

TRANSFORMING THE TREATMENT PARADIGM IN B-CELL MALIGNANCIES

Pharmacist Insights into BTK Inhibitors

- Ahn IE, Tian X, Albitar M, et al. Validation of clinical prognostic models and integration of genetic biomarkers of drug resistance in CLL patients treated with ibrutinib. Abstract 696. Presented at: 2018 ASH Annual Meeting; December 3, 2018; San Diego, California.
- Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. *Blood*. 2017;129(11):1469–1479.
- Allan JN, Wierda WG, Patel K, et al. Preliminary safety, pharmacokinetic, and pharmacodynamic results from a phase Ib/II dose-escalation and cohort-expansion study of the noncovalent, reversible Bruton's tyrosine kinase inhibitor (BTKi), vecabrutinib, in B-Lymphoid malignancies. Abstract 3141. Presented at: 2018 ASH Annual Meeting; December 2, 2018; San Diego, California.
- Ball S, Vutthikraivit W, Das A, et al. Risk of infection with ibrutinib in patients with B-cell malignancies: a meta-analysis of phase III randomized controlled trials. Abstract 2871. Presented at: 2018 ASH Annual Meeting; December 2, 2018; San Diego, California.
- Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): A covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. *J Pharmacol Exp Ther*. 2017;363(2):240–252.
- Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. *Blood*. 2017;129(19):2612–2615.
- Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase III results from RESONATE-2. *Haematologica*. 2018;103(9):1502–1510.
- Barr P, Robak T, Owen CJ, et al. Updated efficacy and safety from the phase III Resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia/small lymphocytic leukemia. *Blood*. 2016;128(22):234.
- Brown JR. How I treat CLL patients with ibrutinib. *Blood*. 2018;131(4):379–386.
- Bruton's tyrosine kinase: an exciting new target for treatment of B-cell malignancies. *Cancer Therapy Advisor*. January 12, 2012. <https://www.cancertherapyadvisor.com/home/cancer-topics/hematologic-cancers/brutons-tyrosine-kinase-an-exciting-new-target-for-treatment-of-b-cell-malignancies/>. Accessed March 2019.
- Burger JA, O'Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy. *Nat Rev Clin Oncol*. 2018;15(8):510–527.
- Burger JA, Tedeschi A, Barr PM, et al. RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med*. 2015;373(25):2425–2437.
- Bye AP, Unsworth AJ, Desborough MJ, et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib [published correction appears in: *Blood Adv*. 2018;2(23):3515]. *Blood Adv*. 2017;1(26):2610–2623.
- Byrd JC, Brown JR, O'Brien S, et al. RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014;371(3):213–223.
- Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. *Blood*. 2015;125(16):2497–2506.
- Byrd JC, Harrington B, O'Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. *N Engl J Med*. 2016;374(4):323–332.

- Byrd JC, Hillmen P, James DF. Response: Additional data needed for a better understanding of the potential relationship between atrial fibrillation and ibrutinib. *Blood*. 2015;125(10):1673.
- Byrd JC, Hillmen P, O'Brien S, et al. Long-term follow-up of the RESONATE phase III trial of ibrutinib versus ofatumumab. *Blood*. March 6, 2019. [Epub ahead of print.]
- Byrd JC, Smith S, Wagner-Johnston N, et al. First-in-human phase I study of the BTK inhibitor GDC-085 in relapsed or refractory B-cell NHL and CLL. *Oncotarget*. 2018;9(16):13023–13035.
- Byrd JC, Wierda WG, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from the phase I/II ACE-CL-001 study. *Blood*. 2017;130(Suppl 1):498.
- Byrd JC, Woyach JA, Furman RR, et al. Acalabrutinib in treatment-naïve (TN) chronic lymphocytic leukemia (CLL): updated results from the phase I/II ACE-CL-001 study. Abstract 692. Presented at: 2018 ASH Annual Meeting; December 1, 2018; San Diego, California.
- Chamilos G, Lionakis MS, Kontoyiannis DP. Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways. *Clin Infect Dis*. 2018;66(1):140–148.
- Chanan-Khan A, Cramer P, Demirkan F, et al. HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase III study. *Lancet Oncol*. 2016;17(2):200–211.
- Cuní S, Pérez-Aciego P, Pérez-Chacón G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. *Leukemia*. 2004;18(8):1391–1400.
- de Weerd I, Koopmans SM, Kater AP, et al. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. *Haematologica*. 2017;102(10):1629–1639.
- de Weers M, Brouns GS, Hinshelwood S, et al. B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia. *J Biol Chem*. 1994;269(39):23857–23860.
- Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase III trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. *N Engl J Med*. 2018;378(25):2399–2410.
- Dimopoulos MA, Trotman J, Tedeschi A, et al. iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label sub-study of an international, multicentre, phase III trial. *Lancet Oncol*. 2017;18(2):241–250.
- Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase III study [published correction appears in: *Lancet*. 2016;387(10020):750]. *Lancet*. 2016;387(10020):770–778.
- Drugs@FDA. FDA approved drug products: acalabrutinib. Updated October 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf. Accessed March 2019.
- Drugs@FDA. FDA approved drug products: copanlisib. Updated September 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf. Accessed March 2019.
- Drugs@FDA. FDA approved drug products: duvelisib. Updated September 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf. Accessed March 2019.
- Drugs@FDA. FDA approved drug products: ibrutinib. Updated January 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s026,210563s002lbl.pdf. Accessed March 2019.

- Drugs@FDA. FDA approved drug products: idelalisib. Updated July 2014.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206545lbl.pdf. Accessed March 2019.
- Falchi L, Baron JM, Orlikowski CA, et al. BCR signaling inhibitors: an overview of toxicities associated with ibrutinib and idelalisib in patients with chronic lymphocytic leukemia. *Mediterr J Hematol Infect Dis*. 2016;8(1):e2016011.
- Ghez D, Calleja A, Protin C, et al. French Innovative Leukemia Organization (FILO) CLL group. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. *Blood*. 2018;131(17):1955–1959.
- Hillmen P, Rawstron A, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the Bloodwise TAP Clarity Study. Abstract 182. Presented at: 2018 ASH Annual Meeting; December 1, 2018; San Diego, California.
- Hunter ZR, Xu L, Tsakmaklis N, et al. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. *Blood Adv*. 2018;2(21):2937–2946.
- Jegaraj BMC, Scheffold A, Tausch E, et al. Vencabrutinib is efficacious in vivo in a preclinical CLL adoptive transfer model. Abstract 1868. Presented at: 2018 ASH Annual Meeting; December 1, 2018; San Diego, California.
- Jones JA, Hillmen P, Coutre S, et al. Use of anticoagulants and antiplatelets in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. *Br J Haematol*. 2017;178(2):286–291.
- Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. *Blood*. 2017;129(4):473–483.
- Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. *Blood*. 2016;128(1):138–140.
- Li T, Tsukada S, Satterthwaite A, et al. Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. *Immunity*. 1995;2(5):451–460.
- Mahajan S, Ghosh S, Sudbeck EA, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. *J Biol Chem*. 1999;274(14):9587–9599.
- Merolle MI, Ahmed M, Nomie K, et al. The B-cell receptor signaling pathway in mantle cell lymphoma. *Oncotarget*. 2018;9(38):25332–25341.
- Mertens D, Stilgenbauer S. Ibrutinib-resistant CLL: unwanted and unwonted! *Blood*. 2017;129(11):1407–1409.
- Moreno C, Greil R, Demirkan F, et al. Ibrutinib + obinutuzumab versus chlorambucil + obinutuzumab as first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL): results from phase III iLLUMINATE. Abstract 691. Presented at: 2018 ASH Annual Meeting; December 3, 2018; San Diego, California.
- Nastoupil LJ, Lee HJ, Hagemeister FB, et al. Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular and marginal zone lymphoma: an open label, phase II study. Abstract 447. Presented at: 2018 ASH Annual Meeting; December 2, 2018; San Diego, California.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. NCCN website. Version 4.2019. March 15, 2019.
https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed March 2019.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Mantle Cell Lymphoma. NCCN Website. Version 2.2019. March 6, 2019. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed April 2019.
- Nihiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. *Nat Rev Immunol*. 2002;2(12):945–956.
- Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. *Blood*. 2017;129(16):2224–2232.

- Owen R, McCarthy H, Rule S, et al. Acalabrutinib in patients (pts) with Waldenstrom macroglobulinemia (WM). Abstract 7501. Presented at: the American Society of Clinical Oncology Annual Meeting; June 3, 2018; Chicago, Illinois.
- Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. *J Biol Chem*. 2001;276(3):1715–1719.
- Phillips TJ, Smith SD, Jurczak W, et al. Safety and efficacy of acalabrutinib plus bendamustine and rituximab (BR) in patients with treatment-naive (TN) or relapsed/refractory (R/R) mantle cell lymphoma (MCL). Abstract 4144. Presented at: 2018 ASH Annual Meeting; December 3, 2018; San Diego, California.
- Pollyea DA, Jones CL, Stevens BM, et al. Relapsed acute myeloid leukemia is less sensitive to venetoclax + azacitidine due to leukemia stem cell resistance driven by fatty acid metabolism and can be overcome by pharmacologic inhibition of CPT1. Abstract 432. Presented at: 2018 ASH Annual Meeting; December 2, 2018; San Diego, California.
- Quek LS, Bolen J, Watson SP. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. *Curr Biol*. 1998;8(20):1137–1140.
- Rameh LE, Arvidsson Ak, Carraway KL, et al. A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. *J Biol Chem*. 1997;272(35):22059–22066.
- Rawlings DJ, Scharenberg AM, Park H, et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. *Science*. 1996;271(5250):822–825.
- Rogers KA, Luay M, Zhao Q, et al. Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center. *Blood*. 2017;130(Suppl 1):830.
- Rule S, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase III, international, randomized, open-label RAY study. *Leukemia*. 2018;32(8):1799–1803.
- Shanafelt TD, Wang V, Kay NE, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Abstract LBA-4. Presented at: 2018 ASH Annual Meeting; December 4, 2018; San Diego, California.
- Shatzel JJ, Olson SR, Tao DL, et al. Ibrutinib-associated bleeding: pathogenesis, management, and risk reduction strategies. *J Thromb Haemost*. 2017;15(5):835–847.
- Shillitoe B, Gennery A. X-linked agammaglobulinemia: outcomes in the modern era. *Clin Immunol*. 2017;183:54–62.
- Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. *N Engl J Med*. 2018;378(13):1211–1223.
- Tan JE, Wong SC, Gan SK, et al. The adaptor protein BLNK is required for B-cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes. *J Biol Chem*. 2001;276(23):20055–20063.
- Thomas JD, Sideras P, Smith CI, et al. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. *Science*. 1993;261(5119):355–358.
- U.S. National Library of Medicine. ClinicalTrials.gov. <https://clinicaltrials.gov/>. Accessed March 2019.
- Varughese T, Taur Y, Cohen N, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. *Clin Infect Dis*. 2018;67(5):687–692.
- Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. *Blood*. 2015;126(6):739–745.

- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2013;369(6):507–516.
- Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase II trial. *Lancet*. 2018;391(10121):659–667.
- Wang M, Rule S, Zinzani PL, et al. Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma. Abstract 2876. Presented at: 2018 ASH Annual Meeting; December 2, 2018; San Diego, California.
- Wiczner TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. *Blood Adv*. 2017;1(20):1739–1748.
- Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. *Haematologica*. 2015;100(12):1495–1507.
- Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nat Med*. 2015;21(8):922–926.
- Woyach JA, Farrukh TA, Jianfar M, et al. Acalabrutinib with obinutuzumab in relapsed/refractory and treatment-naïve patients with chronic lymphocytic leukemia: the phase Ib/II ACE-CL-003 study. *Blood*. 2017;130:432.
- Woyach JA, Flinn IW, Stephens DM, et al. A phase I dose escalation study of ARQ 531 in selected patients with relapsed or refractory hematologic malignancies. Abstract 3136. Presented at: 2018 ASH Annual Meeting; December 2, 2018; San Diego, California.
- Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor, ibrutinib. *N Engl J Med*. 2014;370(24):2286–2294.
- Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N Engl J Med*. 2018;379(26):2517–2528.
- Wu J, Liu C, Tsui ST, et al. Second-generation inhibitors of Bruton tyrosine kinase. *J Hematol Oncol*. 2016;9(1):80.
- Yan Q, Huang Y, Watkins AJ, et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. *Haematologica*. 2012;97(4):595–598.